Role of Hypersensitivity to Female Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss

Sponsor

EVE Medical Systems Ltd. (Industry)

Overall Status

Unknown status

CT.gov ID

NCT01175759

Collaborator

Semmelweis University (Other)

Enrollment

Location

Arms

Duration (Months)

2.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The EVE- technology is intended for determination of intolerance or sensitivity to female sex hormones among women with hormone-related conditions and for further treatment by desensitization procedure inducing a tolerance to the hormones the women are sensitive to.

This study is designed to evaluate the safety and the ability of the EVE- Skin-Test Panel to detect sensitivity to female sex hormones in subjects with Unexplained Recurrent Pregnancy Loss (URPL) and in Control parous, healthy women.

The Skin Test Panel includes four female hormones and three control solutions.

Hormones from the Skin Test Panel are injected intradermally during the luteal phase of the subject's menstrual cycle. The skin reactions are examined by physician for erythema and wheal after 20 minutes and 48 hours and self-assessed by the patient daily for the following month.

Skin response monthly data is analyzed and compared between unexplained recurrent pregnancy loss (UPRL) and healthy groups.

Following achievement of the significant differences between both groups the immune profile of the healthy and UPRL subjects will be investigated.

Condition or Disease	Intervention/Treatment	Phase
Abortion, Recurrent	Drug: Skin test panel Drug: Skin test panel	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

40 participants

Allocation:

Non-Randomized

Intervention Model:

Factorial Assignment

Masking:

None (Open Label)

Primary Purpose:

Diagnostic

Official Title:

Evaluation of the Efficacy and Safety of the EVE- Skin-Test Panel in Detecting Sensitivity to Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss

Study Start Date :

Jun 1, 2010

Anticipated Primary Completion Date :

Jun 1, 2011

Anticipated Study Completion Date :

Dec 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Healthy control group	Drug: Skin test panel Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators. Hormones: Progesterone 1mmol/L Estradiol 1mmol/L Estrone 3mmol/L Estriol 3mmol/l Controls: Saline (NaCl) 0.9% Ethyl Oleate with 10% Benzyl Alcohol Histamine phosphate 1mg/ml (epicutaneous- prick test)
Experimental: UPRL	Drug: Skin test panel Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators. Hormones: Progesterone 1mmol/L Estradiol 1mmol/L Estrone 3mmol/L Estriol 3mmol/l Controls: Saline (NaCl) 0.9% Ethyl Oleate with 10% Benzyl Alcohol Histamine phosphate 1mg/ml (epicutaneous- prick test)

Arm

Intervention/Treatment

Experimental: Healthy control group

Drug: Skin test panel

Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators. Hormones: Progesterone 1mmol/L Estradiol 1mmol/L Estrone 3mmol/L Estriol 3mmol/l Controls: Saline (NaCl) 0.9% Ethyl Oleate with 10% Benzyl Alcohol Histamine phosphate 1mg/ml (epicutaneous- prick test)

Experimental: UPRL

Drug: Skin test panel

Outcome Measures

Primary Outcome Measures

Number of subjects with positive wheal responses to the Skin Test Panel in URPL and Control groups [1 month]

Secondary Outcome Measures

Frequency and severity of adverse events following a skin test procedure in subjects from URPL and Control groups [1 month]
Measurement of cytokine production in subjects from UPRL and Control groups [1 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 40 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

For both groups:

Between ages of 20 to 40
Willing to participate as shown by signing the informed consent form.

For healthy group:

Parous subjects without premenstrual syndrome, as per medical history and subject's report ( PMS questionnaire)

For UPRL:

Women with three or more documented early pregnancy losses.

Exclusion Criteria:

For both groups:

No hormonal contraceptives (either OC or hormonal IUD (Mirena)), no psychotropic agents (e.g. Antidepressants, anxiolytics, or lithium carbonate) for at least two months prior to screening.
No hormonal therapy (estrogen or progesterone) for at least two months prior to screening.
Significant medical or psychiatric disease.
Severe allergies or an inflammatory illness at the time of enrollment

For healthy group:

Women who are pregnant or lactating on the day of screening
Abnormal routine blood tests

For UPRL:

Hereditary thrombophilias (Factor V Leiden, Activated protein C resistance, MTHFR (C677T), Factor II mutation (G20201A))
One or more abnormal test from the list below:
Karyotype of either parent (normal: 46XX or 46XY)
Glucose tolerance test (This can be altered to fasting blood sugar of 100mg/dl or less);
Toxoplasmosis serology (IgM positive);
Hysterosalpingogram, 3-D ultrasound or hysteroscopy, thereby excluding anatomical abnormalities, intrauterine adhesions and cervical incompetence;
Thyroid function (Euthyroid levels;);
Serum prolactin;
Normal luteal phase of at least 12 days and plasma progesterone above 24 ng/lL
Anti nuclear factor (Negative)
Anticardiolipin antibody by Elisa testing (cut off value <13 GPLu/mL and <7.6 MPLu/mlL) and Lupus anticoagulant (according to Kaolin clotting time (KCT), Russell's viper venom tome (RVVT) or APTT.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Depts. Gynecology and Obstetrics and 3rd Dept of Internal Medicine	Budapest		Hungary	H1125

Sponsors and Collaborators

EVE Medical Systems Ltd.
Semmelweis University

Investigators

Principal Investigator: János Rigó, Prof., Gynecology and Obstetrics Dept, Semmelweis University, Budapest, Hungary
Principal Investigator: Henriette Farkas, Prof., 3rd Dept of Internal Medicine, Semmelweis University, Budapest, Hungary